ClinicalTrials.gg
RecruitingNCT07214675WOLVERINEUpdated Apr 9, 2026

The Edison System for Treatment of Benign Prostatic Hyperplasia (BPH) Using Histotripsy

An interventional study of HistoSonics Edison System in Benign Prostatic Hyperplasia, sponsored by HistoSonics, Inc.. Recruiting at 1 site in Hong Kong. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by HistoSonics, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Prostatic Hyperplasia with a site in Hong Kong — 7 open to participants now, 8 under way, none of them phase 3. Prostatic Hyperplasia · Hong Kong.

Planned enrollment
8th of 14
80 · median 81
Started
2026
with 3 others
No phase
14 of 17
5 open now
Registered
14th of 17
by date
Lead sponsor
1 of 17
HistoSonics, Inc.

Among the 17 studies in Prostatic Hyperplasia with a site in Hong Kong, this one is the 8th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2026, is one of 14 with no phase, and was the 14th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

7 of the 17 studies in Prostatic Hyperplasia with a site in Hong Kong are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Prostatic Hyperplasia with a site in Hong Kong, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the safety of histotripsy using the HistoSonics Edison System for treatment of BPH.

Read the detailed description

This is a prospective multi-center, single-arm, feasibility trial designed to evaluate the safety of the HistoSonics Histotripsy System for treatment of BPH. Following histotripsy, subjects will undergo imaging ≤ 72 hours post-index procedure. Additionally, subjects will be followed at 30-day, 90-day and 180-day timepoints.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥ 50 years of age.
  2. Subject has signed the Ethics Committee (EC) approved trial Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
  3. Subject is diagnosed with BPH.
  4. Subject has a (BMI) \< 27.
  5. Subject has an I-PSS ≥ 15.
  6. Subject has a prostate volume > 30 mL and ≤ 150 mL.
  7. Subject has a Qmax ≤ 15 mL/s with a voided volume of ≥ 125 mL during a uroflow test.
  8. Subject accepts the potential loss of ejaculatory function.
  9. Subject can tolerate general anesthesia. Index-Procedure Imaging Inclusion (Assessed day of procedure)
  10. Subject has an adequate acoustic window to visualize the prostate using the HistoSonics Edison System.
  11. Target treatment volume is ≥ 1 cm from the rectum as visualized on ultrasound, CT or MR imaging.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a of less than one (1) year.
  2. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
  3. Subject has a post-void residual ≥ 150 mL confirmed via ultrasound.
  4. Subject has an estimated (eGFR) ≤ 50 mL/min, ≤ 14 days prior to the planned index procedure date.
  5. Subject has uncorrectable coagulopathy.
  6. Subject has an (INR) value ˃ 2.0, ≤14 days prior to the planned index procedure date.
  7. Subject has had a prostatectomy.
  8. Subject has acute prostatitis.
  9. Subject has a diagnosis of or has received treatment for chronic prostatitis or chronic pelvic pain syndrome.
  10. Subject has had a urinary tract infection (UTI) ≤ 3 months prior to the planned index procedure date.
  11. Subject has bladder stones.
  12. Subject is catheter dependent or has a history of intermittent self-catheterization.
  13. Presence of prostatic calcifications in the planned treatment volume (PTV).
  14. Presence of permanent radioactive implants in the rectal wall.
  15. Subject has has a major abdominal or rectal surgery that inhibits visualization of the prostate.
  16. Subject has undergone prior locoregional therapy (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).
  17. Subject has planned locoregional therapy 6 months post index procedure (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).
  18. Subjects who have active cancers (not in remission for the last two years) other than non-melanomatous skin cancers.
  19. Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.
  20. In the investigator's opinion, histotripsy is not a treatment option for the subject.
  21. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
  22. Subject's prostate is not treatable by the System's working ranges (refer to User Guide).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    HistoSonics Edison System

    Device: HistoSonics Edison System

Interventions

  • DeviceHistoSonics Edison System

    The HistoSonics Edison System is intended for the non-invasive mechanical destruction of prostate tissue for the treatment of BPH using histotripsy, a non-thermal, mechanical process of focused ultrasound.

    Also known as: Histotripsy

06

What researchers measure

Primary outcomes

  1. Number of Index-Procedure Related Adverse Events Classified by Clavien-Dindo Classification and Common Terminology Criteria for Adverse Events (CTCAE)

    Index procedure-related complications ≤30 days post index procedure, graded using Clavien-Dindo Classification and Common Terminology Criteria for Adverse Events (CTCAE). \[Clinical Events Committee Adjudicated\]

    Time frame: 30 days post histotripsy procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for May 2027, 14 months after the start.

Of 52 industry-sponsored interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 50. This study's planned 14 months is below that.

Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2025
First posted
Oct 9, 2025
StartActual
Mar 20, 2026
Primary completionEst.
May 2027
CompletionEst.
Oct 2027
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07214675
Lead sponsor
HistoSonics, Inc.
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Mar 20, 2026
Primary completion
May 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Apr 9, 2026

Study contacts

Kelly Erickson
Contact
Kelly.Erickson@histosonics.com
612-965-8895

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion